Paper Report for: Mohamed_2011_Bioorg.Med.Chem.Lett_21_5881
Reference
Title: Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Abeta-aggregation inhibitors: Synthesis and biological evaluation Mohamed T, Yeung JC, Rao PP Ref: Bioorganic & Medicinal Chemistry Lett, 21:5881, 2011 : PubMed
A group of 2-substituted N-(naphth-1-ylmethyl)pyrimidin-4-amines (6a-k) and N-benzhydrylpyrimidin-4-amines (7a-k) in conjunction with varying steric and electronic properties at the C-2 position were designed, synthesized and evaluated as dual cholinesterase and amyloid-beta (Abeta)-aggregation inhibitors. The naphth-1-ylmethyl compound 6f (2-(4-cyclohexylpiperazin-1-yl)-N-(naphth-1-ylmethyl)pyrimidin-4-amine) exhibited optimum dual ChE (AChE IC(50)=8.0 muM, BuChE IC(50)=3.9 muM) and hAChE-promoted Abeta-aggregation inhibition (30.8% at 100 muM), whereas in the N-benzhydryl series, compound 7f (N-benzhydryl-2-(4-cyclohexylpiperazin-1-yl)pyrimidin-4-amine) exhibited optimum combination of dual ChE (AChE IC(50)=10.0 muM, BuChE IC(50)=7.6muM) and hAChE-promoted Abeta-aggregation inhibition (32% at 100 muM). These results demonstrate that a 2,4-disubstituted pyrimidine ring serves as a suitable template to target multiple pathological routes in AD, with a C-2 cyclohexylpiperazine substituent providing dual ChE inhibition and potency whereas a C-4 diphenylmethane substituent provides Abeta-aggregation inhibition.
        
Related information
Citations formats
Mohamed T, Yeung JC, Rao PP (2011) Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Abeta-aggregation inhibitors: Synthesis and biological evaluation Bioorganic & Medicinal Chemistry Lett21: 5881-7